clusterin (CLU), is upregulated in response to cellular stress (e.g., chemotherapy, radiation) and promotes cancer cell survival, EMT, and immune evasion. Sotevtamab's blockade of clusterin disrupts these pathways, potentially reversing therapy resistance, inhibiting metastatic spread, and enhancing tumor cell death in clusterin-overexpressing malignancies.